Objectives
To evaluate the response of human cholangoicarcinoma cells to TMX treatment through the Fas pathway by pretreatment with IFN-␥.
Summary Background Data
Cholangiocarcinoma remains one of the most difficult tumors to treat in clinical medicine. Currently, there are no effective chemotherapy treatments for this disease. Surgery offers the only opportunity for a cure, with the majority of patients failing to qualify for such treatment. This study seeks to evaluate a potential new modality for treatment of this disease.
Methods
Human cholangiocarcinoma cells were treated with anti Fas mab and sorted to two populations (Fas-positive and Fasnegative) by FAC analysis. In vitro individual cell populations were pretreated with IFN-␥ 250 units/mL ϫ 18hs. The treated cells assayed for caspase 3, 7, 8, Bak, and for apoptosis with Annexin V after treatment with or without TMX. In Vivo 2 ϫ 10 6 5 SK-ChA-1 Fas-negative cells were injected into nude mice for development of tumor xenografts. Mice received either no treatment or intra tumor IFN-␥ and/or intra peritoneal TMX.
Results
More than 90% (90% Ϯ 3.5%) of Fas-positive and 70% (71 Ϯ 2.3%) of Fas-negative cells underwent apoptosis after TMX treatment when pretreated with IFN-␥. In contrast, TMX alone and IFN-␥ alone stimulated apoptosis by only 22% (22 Ϯ 3%) P Ͻ .00013, and 17% (17 Ϯ 2%) P Ͻ .0001 in Fas-ve cells respectively.
In vivo human cholangiocarcinomas xenograft growth was significantly inhibited by a combination of TMX ϩ IFN-␥ compared to controls P Ͻ .0007.
Conclusion
TMX exposure to human cholangiocarcinoma after pretreatment with IFN-␥ allows for induction of apoptosis in vitro and significant inhibition tumor xenograft growth. The combination of these two compounds may provide novel treatment regimen for cholangiocarcinoma.
Cholangiocarcinoma is a highly malignant tumor of the bile ducts with no effective therapy and a poor long-term prognosis. 1 This tumor has an increasingly frequent diagnosis worldwide, [2] [3] [4] [5] but information about the molecular pathogenesis of cholangiocarcinoma is lacking. In this re-gard, curative therapeutic intervention is limited by the advanced disease stage of most patients at initial presentation and the lack of effective chemotherapy. [2] [3] [4] [5] At diagnosis, approximately 30% of patients are candidates for attempted curative surgical resection. Of these patients, 70% are found to have occult metastatic or locally advanced disease, precluding curative resection. Surgical cures do occur; however, the majority of patients undergoing attempted curative resection develop recurrent disease at the anastomotic site or within the intrahepatic biliary tree, and succumb due to progression of disease, hepatic failure, or cholangitis. 6 Furthermore, strictly nonoperative attempts at palliation of obstructive jaundice include either percutaneous or endoscopically placed stents across the obstructing mass, and survival varies from 3 to 6 months. [7] [8] [9] The overall survival following diagnosis of cholangiocarcinoma is less than 12% at 5 years. 10, 11 Fas (CD95) is a type I membrane protein and a member of TNF receptor (TNFR) family. 12, 13 Fas is abundantly expressed in the lymphocyte, heart, liver lung, kidney, and ovary. On the other hand, Fas ligand (FasL), a type II membrane protein, is expressed in activated T lymphocytes, NK cells, and tissues of immune-privileged sites such as eyes, testis, and developing nervous system. 14, 15 Fas and/or FasL are expressed in many tumor cells and tumor cell lines, 14 -21 suggesting that Fas/FasL may be involved in the pathogenesis of malignant transformation.
Fas is expressed heterogeneously in the human cholangiocarcinoma cell line, SK-ChA-1, resulting in two subpopulations: Fas-positive and Fas-negative cells. 23 Interestingly, only Fas-negative cells were tumorigenic in nude mice. [23] [24] [25] The interferons (IFNs) were initially recognized for their ability to interfere with viral replication, and have been shown to inhibit growth, induce cell differentiation, and modulate the immune response. 26 -31 However, the mechanism by which IFN-␥ induces growth inhibition in tumor cells has not been elucidated. Here, we report that IFN-␥ enhances Fas-mediated apoptosis, which involves mitochondria in both Fas-positive and Fas-negative human cholangiocarcinoma cells via up-regulation of Bak and apoptotic caspase proteins. We also demonstrate that TMX and IFN-␥ are antitumorigenic in nude mice engraftment experiments with Fas-negative cells, suggesting a possible therapeutic modality.
MATERIALS AND METHODS

Cells and Cell Culture
The human cholangiocarcinoma cell line, SK-ChA-1 (WITT) was provided by Dr. A. Knuth (Ludwig Institute for Cancer Research, London, United Kingdom). Cells were grown in RPMI1640 (Life Technologies, Inc., Gaithersburg, MD) supplemented with 2 mmol/L L-glutamine, penicillin (5 units/mL), Streptomycin (5 g/mL) and 10% heat-inactivated fetal bovine serum.
Antibodies and Reagents
Human activating Fas antibody (clone CH11) was obtained from Upstate Biotechnology (Lake Placid, NY) or antibody (C-20) was from Santa Crus Biotechnology (Santa Cruz, CA). Antibody for caspase 3 and Bak Western blot and PE-conjugated antihuman Fas antibody were purchased from PharMingen (San Diego, CA). Recombinant human IFN-␥ was purchased from R&D Systems (Minneapolis, MN). TMX was purchased from Sigma (St. Louis, MO).
Mice
Athymic (nu/nu) female BALB/c mice, 6 to 8 weeks of age, were purchased from Charles River Laboratories (Wilmington, MA) for tumor inoculation and IFN-␥ treatment. All animals were maintained in a sterile environment. Cages, bedding, food, and water were autoclaved and animals were maintained on a daily 12-hour light/12-hour dark cycle.
Measurement of Surface Fas Expression by Flow Cytometry
Cells were harvested, resuspended in FACS buffer (phosphate-buffered saline with 5% fetal bovine serum, 0.1% sodium azide) and labeled with PE-conjugated Fas antibody at room temperature for 20 minutes. After washing twice with FACS buffer, cells were fixed with 1% paraformaldehyde and analyzed on the FACScan (Becton Dickinson, Mountain View, CA).
RNase Protection Assay
Total RNAs were isolated using RNAgents (Promega, Madison, WI) and Multi-probe RNase protection assay was performed according to the manufacturer's directions for RiboQuant (PharMingen, San Diego, CA). 32 P-labeled antisense RNA probes were prepared using human apoptosis multi-probe sets, hAPO-3c and hAPO-1c (PharMingen).
Preparation of Whole Cell Lysates
Cells were washed with phosphate-buffered saline (PBS) and lysed in SDS lysis buffer (100 mmol/L Tris-HCl, pH8.0, 150 mmol/L NaCl, 1% SDS, 10% glycerol, 5 mmol/L EDTA, 5 mmol/L EGTA, 2 mmol/L Phenylmethylsulfonyl fluoride, 1 g/mL Pepstatin and Leupeptin).
Western Blotting
Whole cell lysates (20 g) were separated by 12 or 15% SDS-polyacrylamide gel electrophoresis and transferred to Immobilon P membranes (Millipore, Bedford, MA). Membranes were blocked in Tris-buffered saline (TBS) containing 2% nonfat milk powder and 0.1% Tween 20. They were incubated with primary antibodies for caspase 3, and Bak followed by incubation with antimouse or antirabbit horseradish peroxidase-conjugated antibodies (Amersham Pharmacia Biotech, Piscataway, NJ). Blots were developed by enhanced chemiluminescence (Amersham Pharmacia Tiotech). tection kit (Medical & Biologic Laboratories, Japan). After incubations with 250 units/mL of IFN-␥ for 18 hours and subsequent treatment with 10 mol/L TMX for 24 hours, 1 ϫ 10 5 cells were harvested and resuspended in 200 L of binding buffer (Medical & Biologic Laboratories). Annexin V-FITC and PI were added, followed by incubation at room temperature for 5 minutes. Annexin V binding and PI staining were analyzed by flow cytometry.
In Vivo Tumor Growth Inhibition by TMX and IFN-␥ Treatment
Cultured Fas-negative SK-ChA-1 human cholangiocarcinoma cells were trypsinized, washed, and resuspended in Dulbecco's PBS (Cell Grow). Mice were anesthetized with isoflurane inhalation, then 5 ϫ 10 6 cells were inoculated subcutaneously into the flank of mice using a 22-gauge needle in a total volume 0.2 mL/site. Four days later, TMX IFN-␥ treatments were initiated. At each treatment, mice were injected with IFN-␥ and/or TMX 5 ϫ 10 4 units of IFN-␥ in 0.1 mL PBS was injected into the area where cells were injected TMX 0.1 mg/kg in peanut oil was injected the intraperitoneal space 3 times per week/4 weeks. Mice in the control arm of the study were injected with PBS. After 3 cycles of 3 daily injections of IFN-␥ and/or TMX with 1 injection-free day between cycles, diameters of the tumors were measured.
Tumor volume ϭ ͑/6͒ ϫ ͑diameter͒ 3
Statistical Analysis
Statistical significance of In vitro Annexin V data and In vivo tumor measurements at 6 weeks were determined by Fisher exact T-test.
RESULTS
Human Cholangiocarcinoma Cells Heterogeneously Express Fas
The human cholangiocarcinoma cell line SK-ChA-1 can be separated into two subpopulations: Fas-positive and Fasnegative cell lines. 23 We show here that Fas-negative cells express some Fas, as determined by flow cytometry. Using flow cytometry, about 98% of Fas-positive cells were shifted into M2 region (PE-staining positive region), whereas only 45% of Fas-negative cells were in that region (Data not shown).
Interferon-Gamma (IFN-␥) Induces Susceptibility to TMX-Mediated Apoptosis in Human Cholangiocarcinoma Cells
In a previous report, we demonstrated that Fas-positive cells are sensitive to apoptosis induced by TMX, but Fas-negative cells were resistant to this treatment. 23 To investigate whether IFN-␥ renders Fas-negative cholangiocarcinoma cells susceptible to TMX-mediated apoptosis, we treated Fas-positive and Fas-negative cells with 250 units/mL of IFN-␥ for 18 hours before incubation with TMX to induce apoptosis. Pretreatment with IFN-␥ enhanced the sensitivity to TMX-mediated apoptosis, both in Fas-positive and Fas-negative cholangiocarcinoma cells ( Fig. 1) . Figure 2 is a summary of four different experiments, with Annexin V-FITC/propidium iodide staining to determine apoptotic cell death. TMX alone killed only Faspositive cells, and 18 hours treatment of IFN-␥ alone was not enough to significantly induce apoptosis. However, when cells were pretreated with IFN-␥, followed by stimulation with TMX, Fas-negative cells became sensitive to Fas-mediated apoptosis and Fas-positive cells became more sensitive. Annexin V assay Fas-positive cells were extremely sensitive to TMX ϩIFN-␥ treatment (90% Ϯ 3.5) versus IFN-␥ alone (20 Ϯ 2%, P Ͻ .00013) or controls (19 Ϯ 2.3%, P Ͻ .0001), TMX (81 Ϯ 9%). NS Fas-negative cells were resistant to all therapies except TMX and IFN-␥ (71 Ϯ 2.3%) versus controls (9 Ϯ 3%, P Ͻ .00021) and TMX alone (22% Ϯ 3%, P Ͼ .0003) failed to induce apoptosis on the Fas-negative cell.
IFN-␥ Up-Regulates Transcription of Fas, Bak and Caspases 3, 7, 8
To investigate the effect of IFN-␥ on gene transcription, RNase protection assays were performed using antisense RNA probes of Fas and caspases 3, 7, 8 ( Fig. 2A ). Compared with Fas-positive cells, which show expression of Fas mRNA, Fas-negative cells have less (almost undetectable) Fas mRNA, consistent with the low expression of Fas in Fas-negative cells. After IFN-␥ treatment, Fas mRNA was markedly increased in both Fas-positive and Fas-negative cells. In addition, IFN-␥ appears to up-regulate gene transcription of caspases 3, 7, 8, ( Fig. 2A ). Furthermore, IFN-␥ up-regulates Bak expression as determined by Western blot (Fig. 2B) 
Caspase 3 Activation is Involved in IFN-␥ Enhanced TMX-Mediated Apoptosis in Both Fas-Positive and Negative Cholangiocarcinoma Cells
Fas-negative and Fas-positive cells were examined before and after treatment of IFN-␥. TMX induced cleavage of procaspase 3 as indicated by the accumulation of cleaved caspase 3 in Fasϩ but not Fas-cells. However, after treat-ment with IFN-␥, TMX induced accumulate caspase 3 cleavage in both Fasϩ and Fas-cells. (Fig. 2C ).
TMX and IFN-␥ Decreases Tumorigenesis of Fas-Negative Cells in vivo
Previously, we demonstrated that Fas-negative cells (but not Fas-positive) formed tumors when injected subcutaneously into nude mice. 25 Because of the ability of IFN-␥ to convert Fas-negative to Fas-positive cells and enhance TMX-induced apoptosis, we examined the antitumorigenic effect of IFN-␥ with and without TMX in Fas-negative cell tumor xenografts. Four days after subcutaneous injection of Fas-negative cells, we initiated IFN-␥ treatment by injection into the site where cells were injected. Three cycles of 3 
DISCUSSION
Cholangiocarcinoma is a malignant tumor of the bile duct with a 5-year overall survival rate of less than 10%. The prognosis is poor because of the difficulty in making an early diagnosis, and because the tumors are resistant to current forms of therapies. 13 Therefore, new therapeutic modalities are needed. However, our current understanding of the molecular mechanisms of the pathogenesis of cholangiocarcinoma is inadequate. The human cholangiocarcinoma cell line, SK-ChA-1, express Fas heterogeneously. Shimonishi et al. 22 suggested that down-regulation or loss of Fas expression occurs during neoplastic transformation of biliary epithelial cells. Thus, cholangiocarcinoma may escape immune surveillance by alteration of Fas experession.
In the present study, we have focused on the ability of IFN-␥ to sensitize Fas-negative cholangiocarcinoma cells to TMX-mediated apoptosis. TMX, known as an antiestrogen, is commonly used to treat and prevent breast cancer, but the molecular mechanism of TMX-mediated apoptosis is poorly understood. Furthermore, its therapeutic activity in estrogen receptor-negative tumors, such as malignant glioma, 32 implicates the nongenomic antiestrogen actions of TMX. Previous studies from our laboratory have demonstrated TMXinduced apoptosis in Fas-positive cholangiocarcinoma cells. 23 These cells also tested negative for the estrogen receptor, confirming the ability of TMX to induce apoptosis independent of its antiestrogen properties, possibly through Fas-mediated pathway. This TMX-induced apoptotic affect was significantly less evident in Fas-negative cells. Treatment of Fas-positive and Fas -ve cells with IFN-␥ upregulate caspases 3, 7, 8, and Bak, which were also associated with TMX-mediated apoptosis (Fig. 1) . 33 Downstream caspases, caspase-3, 7, 8, were up-regulated by IFN-␥ ( Fig. 2) and caspase 3 was activated by TMX. As expected, Fas-negative cells were still less susceptible than Fas-positive cells to TMX-mediated apoptosis without IFN-␥ treatment. It is possible that an inhibitor(s) of Fasmediated apoptotic pathway may exist (such as members of Bcl-2 family) that regulate the release of proteins from mitochondria and the inhibitor-of-apoptosis proteins (IAPs) family, and which bind procaspases or active caspases to prevent them being activated or to inhibit their activity. 34 Recently, Diablo/Smac, a mitochondrial protein that is released to cytosol during apoptosis, was discovered to bind to IAPs, preventing them from inhibiting apoptosis. [33] [34] The status of apoptosis inhibitors in Fas-negative cholangiocarcinoma cells requires further study.
To investigate the in vivo effect TMX and IFN-␥ on the tumorigenesis in vivo, Fas-negative cells were injected into nude mice and were treated with PBS, IFN-␥ alone, TMX alone, or TMX and IFN-␥. The TMX, IFN-␥, and TMX/ IFN-␥ treated group showed reduced tumor size compared with controls ( Fig. 3) . TMX alone in this model appeared to produce a significant inhibition in tumor growth. This was an unexpected finding and may be due to conversion within the mouse of some Fas-negative cells to Fas-positive cells with resulting sensitivity to TMX-induced apoptosis. Another possibility is that the dose of TMX was higher than that required to induce apoptosis through a Fas related mechanism. In conclusion, these investigations show that IFN-␥ up-regulates various apoptosis-related molecules, including Fas, Bak, and caspase 3, 7, 8. This enhances apoptosis initiated by TMX, leading to inhibition of cholangiocarcinoma growth in vivo. The use of IFN-␥ and/or TMX may provide new therapeutic modality for the treatment of human cholangiocarcinoma. 
Discussion
DR. MARK A. TALAMINI (Baltimore, Maryland): I rise to congratulate Dr. Vickers and his colleagues on an excellent presentation of groundbreaking work. As we all know, the surgical treatment of cholangiocarcinoma is in desperate need of a breakthrough in adjuvant therapy. Dr. Vickers' group has taken this relentless and deadly tumor to the laboratory, where they have carefully dissected the tumor biology, including their findings reported today. Having learned that Fas negative tumor cells are more malignant in behavior, they have zeroed in on that clue and used interferon to induce Fas expression (among other proteins) in a cell culture line, rendering the cells more susceptible to apoptosis when treated with tamoxifen. They have also taken the next important step by applying these novel findings in an animal model. The details of their work are clearly described in an excellent manuscript, which is worthy of your study, and I am grateful for the opportunity to read it well in advance of the meeting. I have a few questions:
First, there appears to be a substantial difference between the augmentation of apoptosis in Fas negative cells pretreated by interferon gamma followed by tamoxifen, and the shrinkage of tumor cells in the nude mice treated with both interferon gamma and tamoxifen. In other words, it looks as if the strategy was more effective in the cell culture model than in tumors implanted into nude mice. Do you think this is due to upregulation of additional TNF receptors, as suggested in the manuscript? Or could this be due to differences in the timing of molecular event between the two models? Or could tumor cell preparation for injection induce unanticipated immunologic events even in the nude mouse model?
Second, this work is obviously leading to exciting possibilities in patients, as your summary suggested. In your eyes, what, if anything, needs to be done further prior to initiating human trials?
Third, how did you choose the time course used in the culture experiments; specifically, 18 hours of interferon treatment followed by 24 hours of tamoxifen? Also, you report that the flow cytometric analysis to determine apoptotic cell death was representative of four separate experiments. Were there any differences among these four experiments? As well, were there any differences in stability of the cell line over the multiple passages used for the experiments? DR. F. CHARLES BRUNICARDI (Houston, Texas): I would like to thank the Association for the privilege of discussing this outstanding study and to thank the authors for a copy of the manuscript.
At the time the Southern Surgical Association was being formed, surgeons such as Drs. Billroth, Kocher, and Halsted were making their groundbreaking advances in the use of surgery to treat cancers. They were able to do this based upon what was then recent scientific advances of the discovery of anesthesia and antisepsis. One hundred and thirteen years later, however, the five-year survival of cholangiocarcinoma is only 12%. 
Treatment of Cholangiocarcinoma
In this century, advances will come from the use of molecular techniques as tumor-specific adjuncts to surgical therapy. In this spirit, I would like to congratulate Dr. Vickers, Dr. Bland, and their colleagues on an outstanding NIH-funded study and presentation. What they have done is use analysis and manipulation of molecular pathways to develop a new strategy to treat cholangiocarcinoma. First, they analyzed the apoptotic pathway and determined that human cholangiocarcinoma cell lines that express the Fas receptor do not form tumors in mice, whereas Fas-negative receptor cells do form tumors.
Secondly, they manipulated the apoptotic pathway by using tamoxifen and interferon gamma to cross receptor cell lines to express Fas receptor and thus inhibit human tumor growth in mice.
I have two questions for Dr. Vickers. First, I didn't hear a link between the tamoxifen and interferon gamma in the activation of the apoptotic pathway. Do you have any evidence of the link between these pathways?
Secondly, in terms of translating the work, do you have any evidence of expression of the Fas receptor in freshly resected human cholangiocarcinoma specimens?
DR. YUMAN FONG (New York, New York): Three quick questions, Dr. Vickers.
First, in translating this to a clinical scenario, one has to be able to deliver the tamoxifen and the gamma interferon in a clinically applicable fashion. In the experiments in this paper, direct injection of tumor is used for the gamma interferon. Do the authors have any data on delivering the gamma interferon either systemically or by other means to the cholangiocarcinoma, as direct injection probably will not be the way that we treat diffuse cholangiocarcinoma in the clinics?
Secondly, using the doses of gamma interferon that were used in these experiments, we and other groups have produced other immunologic effects. The same doses given on three consecutive days stimulate NK cell activity and Kupffer cell activity in animals quite well. Have the authors looked at alternative explanations for the tumor regression? And specifically, have the authors used anti-Fas antibody blockade to see whether the effects of their therapy really are through the Fas receptor?
Thirdly, one of the hypotheses of the current experiment is that by delivery of this combination of agents that the Fas negative tumors might become Fas positive. Have the authors looked in vivo, explanting tumors and then doing flow cytometry to see whether there is any conversion to Fas positive? In the tumors that are left at the end of the treatment, tumors left behind, do they find any Fas positivity in flow cytometric analysis? DR. REID B. ADAMS (Charlottesville, Virginia): One quick question about your combination of gamma interferon and tamoxifen. If your prediction is that the gamma interferon increased Fas expression, do you think tamoxifen is going to play any role in the study? In other words, is there going to be any benefit from the tamoxifen in addition to the gamma interferon that you are going to be giving? DR. SELWYN M. VICKERS (Birmingham, Alabama): Thank you all for the insightful questions, and I will try to address each of them.
Dr. Talamini, I will answer this one first. The timing of giving the Fas inhibitors, or, if you would, the TNF receptor blocker, either the antibody or tamoxifen or interferon gamma, at 18 and 24 hours is based on 2 to 3 years of asking how much time is needed to expose the cells to tamoxifen. We have found that 24 hours was more than adequate. This was deduced through a number of scheduled time points to see where we could identify the maximum time benefits for giving interferon gamma, and 18 hours appeared to be adequate as well.
The next question relates to the model and our results. Our previous work showed that if we could convert a significant number of the cells to Fas positive, or if the majority of the cells put in the nude mouse were Fas positive, they wouldn't form tumors. The Fas negative cells easily produced tumors. We have done several treatment studies of tamoxifen and more often than not this drug would not produce an inhibition of Fas negative cell growth. The current study was unique in the fact that we treated longer and with a slightly higher dose of tamoxifen intraperitoneally, and we saw a greater inhibition than we expected, but the interferon gamma appeared to be the critical factor in producing inhibition of cell growth. Dr. Fong may be correct that even in the nude mouse there may some immunologic action occurring. We have looked at residual tumors. The tumors that have had largest growth -that is, tamoxifen-resistant tumors -were predominantly Fas negative, and those small tumors that have been left have had some expression of Fas, but were mostly Fas negative as well. What other things are necessary for us to look at clinical trials? I think we first have to understand the proper dosing. We haven't given excessive doses of either tamoxifen or interferon gamma. But we must understand the toxicity of both of these drugs, particularly interferon gamma, in the patient population. But I believe it is and can be done.
Dr. Brunicardi asked a critical question: "Have we found any correlation with respect to resected specimens?" This slide shows recently analyzed samples from a study in collaboration with Dr. Ralph Rubin from Johns Hopkins asking the question, "does differentiation and grade correlate with Fas expression?" In fact, Fas is expressed in associated tumor lymphocytes and in the bile duct of many well-differentiated tumors. In our 15 samples no Fas expression was found in the poorly differentiated tumors. So there appears in preliminary work to be an association of Fas expression in well-differentiated tumors and a lack of Fas expression, as you would expect from our study, in those tumors that are poorly differentiated.
Dr. Brunicardi asked if we have seen a mechanistic link. We are continuing to try to sort out this pathway. We believe in some manner probably tamoxifen's effect on calcium and calmodulin plays a role in this activation. How interferon gamma upregulates Fas expression is not clear. At least in the numerous in vitro studies we can convince ourselves that cells can be shown to change their surface expression both by flow cytometry and Western blot and RTPCR, Fas expression, and surface Fas expression. So we feel that it does upregulate Fas. How this links with tamoxifen is not clear, except the fact that we know that an influx of calcium by tamoxifen and its effect on calmodulin plays a crucial role in the activation of apoptotic pathways.
And then the final question. As far as Fas antibody is concerned, in addressing Dr. Fong, we in fact can prevent much of what we see, both in vitro and in vivo, by the Fas antibody that blocks and doesn't activate the receptor. So we can correlate this effect that we see related to the Fas pathway by using the antibody in vitro and in vivo. However, I do think that this work has to be continually dissected out in regard to the immunological effect of interferon gamma. But I think that these may provide a future benefit. Because numerous immune cells express Fas ligand, mobilization of the immune system Kupffer cells or T cells may provide a tumoroidal effect. We believe there is an applicable role for this combination therapy (Tamoxifen and interferon gamma). We have also given the tamoxifen and interferon gamma intraperitoneal and see similar results.
Finally, I am convinced that it will take more than one center to get enough patients. But we are using drugs that are not foreign to our current clinical setting. They are not novel in that light. So FDA approval for them shouldn't be too great and should provide an opportunity to push ahead for clinical trials.
